Journal of Clinical Oncology, 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 27, No 15S (May 20 Supplement), 2009: CRA5507
© 2009 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Dueñas-González, A. Articles by Orlando, M. Search for Related Content PubMed Articles by Dueñas-González, A. Articles by Orlando, M.

Abstract

A phase III study comparing concurrent gemcitabine (Gem) plus cisplatin (Cis) and radiation followed by adjuvant Gem plus Cis versus concurrent Cis and radiation in patients with stage IIB to IVA carcinoma of the cervix

Unidad de Investigacion Biomédica en Cáncer, Mexico City, Mexico; Medical Centre San Roque, Tucuman, Argentina; National Institute of Oncology, Panama, Panama; Siriraj Hospital, Bangkok, Thailand; Institute of Oncology, Sarajevo, Bosnia and Herzegovina; Post Graduate Institute of Medical Education and Research, Chandigarh, India; National Institute of Oncology, Lima, Peru; Eli Lilly and Company, Sydney, Australia; Eli Lilly Interamerica, Buenos Aires, Argentina

CRA5507

The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology.

Author Disclosure

Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Eli Lilly and Company Eli Lilly and Company Eli Lilly

Abstract presentation from the 2009 ASCO Annual Meeting